Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company specializing in therapies for difficult-to-treat cancers, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The conference will be held from September 9-11, 2024, with Actuate scheduled to present on Tuesday, September 10, 2024, at 4:00 PM ET.
The company's presentation will focus on its innovative approach to inhibiting glycogen synthase kinase-3 beta (GSK-3β), targeting cancers such as pancreatic cancer and Ewing sarcoma. The presentation will be available via webcast in the Investor section of Actuate's website. Additionally, Actuate's management team will be available for one-on-one meetings during the conference.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ACTU
On the day this news was published, ACTU declined 0.55%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma, through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. In addition, the management team will be available for one-on-one meetings during the conference.
Details on the presentation:
Format: Corporate Presentation
Date: Tuesday, September 10, 2024
Time: 4:00 PM ET
Webcast Link: click here
The webcast of the presentation will be accessible in the Investor section of the Actuate website
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DDR pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
